Lupin, Biomm join hands for Pegfilgrastim distribution, marketing in Brazil
Mumbai: Global pharma major, Lupin Limited has recently announced that the company has entered into an exclusive distribution and marketing agreement with Biomm SA in Brazil.
Under the terms of agreement, Biomm will distribute and market biosimilar Pegfilgrastim in Brazil.
Pegfilgrastim is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving chemotherapy.
Lupin had earlier received the U.S. FDA acceptance of the Biologics License Application (BLA) for Its proposed biosimilar to Neulasta (pegfilgrastim) through a filing using the 351(k) pathway.
Read also: Lupin, TTP collaborate for Soft-mist Inhalation Technology Platform
Founded in 2002, Biomm's headquarters and factory are in Nova Lima (MG), with capacity to produce 20 mlllion vials of insulin per year. The company focuses on developing biological products and it is pioneer in biotechnological drugs In Brazil.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.